As per the 2021 data from the CDC, every year, 805,000 people in the United States have a heart attack, 605,000 of these result in a first-time heart attack, while 200,000 are caused by previous heart attacks. The major factors driving the market are a rise in the global prevalence of multiple cardiovascular indications, atrial fibrillation, an increase in intracranial and gastrointestinal hemorrhages, and the increasing geriatric population. However, the market is currently reaching its pre-pandemic nature and is expected to witness healthy growth in the coming years. Therefore, the COVID-19 pandemic had a significant impact on the market studied. Additionally, it was observed that several patients with COVID-19 had developed abnormal blood clotting, which increased the use of anticoagulants during the pandemic. For instance, per the data from the American Journal of Cardiovascular Drugs, in 2020, more than 10 clinical trials were in progress to evaluate the potential of factor Xa inhibitors in COVID-19 patients, and research on strategies for the parenteral administration of these drugs was worked upon to be used in critically ill COVID-19 patients. The anticoagulant reversal drugs market is expected to witness a CAGR of 12.01% over the forecast period.ĬOVID-19 significantly impacted the anticoagulant reversal drugs market owing to the increasing pace of research activities on COVID-19 infection. 英文タイトル： Anticoagulant Reversal Drugs Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028).

Andexxa drug